National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Galcanezumab (Emgality®). HTA ID 20052

Galcanezumab is indicated for the prophylaxis of migraine in adults who have at least four migraine days per month.

 

NCPE Assessment Process Complete
Rapid review commissioned 02/12/2020
Rapid review completed 13/01/2021
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of galcanezumab (Emgality®) on the basis of the proposed price relative to currently available therapies.